ABSTRACT
Diabetic papillopathy is an uncommon hyperemic optic disc swelling that occurs in patients with long-standing diabetes, is typically self-resolving with minimal effect on vision, and is likely ischemic in origin. The purpose of the current report is to document the response of diabetic papillopathy to intravitreal injection of bevacizumab [Avastin, Genentech Inc, San Francisco, California, USA], a humanized monoclonal antibody to vascular endothelial growth factor
Subject(s)
Humans , Male , Adult , Diabetic Retinopathy/drug therapy , Vascular Endothelial Growth Factor A/antagonists & inhibitors , Antibodies, Monoclonal/administration & dosage , Angiogenesis Inhibitors/administration & dosage , Injections , Vitreous Body , Treatment OutcomeABSTRACT
We report a case of rapid regression of extensive posterior capsule neovascularization in a 67-year-old diabetic male patient, who developed posterior capsule opacity with neovascularization one year post cataract surgery, after a single injection of intravitreal bevacizumab [Avastin] followed by neodymium:YAG capsulotomy. Rapid regression of the posterior capsule neovascularization, and visual improvement was observed 9 days after the intervention. Posterior capsulotomy was performed successfully without bleeding. Prior to posterior capsulotomy, intravitreal bevacizumab can result in rapid and dramatic regression of posterior capsule neovascularization